摘要
目的:观察吉西他滨(健择)单药治疗老年晚期癌症的疗效、临床受益反应(CBR)及毒性反应。方法:54例Ⅲ/Ⅳ期老年癌症患者采用吉西他滨1000mg/m2,第1、8、15天静滴,每28天为一周期。按WHO标准评估疗效和毒副作用,同时综合评估CBR指标。结果:32例非小细胞肺癌有效率为21.88%,54例中CBR率90.7%,毒副反应很轻,对高龄患者也能耐受。结论:采用吉西他滨单药治疗疗效确切、低毒、安全,可作为老年晚期癌症患者的一线治疗方案。
Purpose:To evaluate the clinical efficacy ,clinical-benefit-response (CBR) and toxicity of gemcitabine single-agent in the treatment of elderly advanced cancer. Methods:54 elderly patients with grade Ⅲ/Ⅳ were treaded with gemcitabine 1 000 mg/m^(2) on day 1,8 and 15 in each 28-day cycle. The clinical efficacy and toxicity were estimated according to the standard of WHO and the CBR was evaluated simultaneously. Results:Of 32 advanced NSCLC patients , obtained the partial response (PR) of 21.88% .The CBR rate of 90.7% was reached in 54 patients. The toxicity was mild and well tolerated for elderly patients. Conclusions:Gemcitabine single-agent in the treatment of elderly advanced cancer is highly effective, low toxic and safe. Therefore, it could be considered as first line therapy for elderly advanced cancer.
出处
《中国癌症杂志》
CAS
CSCD
2005年第2期176-177,180,共3页
China Oncology
关键词
吉西他滨
老年晚期癌症
临床受益反应
gemcitabine
elderly advanced cancer
clinical benefit response
